Close Menu

antibodies

Millipore has launched a new tool on its website that incorporates the pathway maps.

In the first part of a two-part interview, Mann discusses the state of technology in proteomics and what still needs to get done for proteomics to cross to the clinical side.

Industry Briefs: Feb 12, 2009

Premium

Life Technologies, Agilent, Protein Discovery, Sigma-Aldrich, Intus, HealthLinx, Origene

Funding Update for Feb 12, 2009

Premium

Recent NSF Awards in Proteomics and Protein Research

Millipore is betting that the buy, which is expected to close in the next several weeks, will provide its customers a powerful cell biology/protein expression-analysis tool for the benchtop.

Industry Briefs: Feb 5, 2009

Premium

Thermo Fisher Scientific, Agilent, NHLBI, Journal of Proteome Research, Roche, Fluorotechnics, and more.

Without specific guidance from the FDA regarding KRAS testing, drugmakers Bristol-Myers Squibb and Amgen are facing lower sales of their colorectal cancer drugs Erbitux and Vectibix, and may need to get creative in how they market their drugs to patients and doctors.

New Product Watch: Feb 3, 2009

Premium

Navigenics, ImaGenes, Ocimum Biosolutions

Proteins, Front and Center

Premium

Once a tool that only piqued the interest of technology developers, protein microarrays have come into their own as scientists find new ways to apply them in basic and translational studies.

The Realm of Noncoding RNAs

Premium

Small (and not-so-small) noncoding RNAs have thrown a spanner in the works of understanding genome function. We take a look at the major questions brought about by micro-RNA, Piwi-interacting RNA, and more.

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.